Oral but not intravenous (IV) diltiazem impairs lovastatin clearance

D. R. Jones, N. B. Azie, A. Masica, D. C. Brater, S. D. Hall

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Lovastatin is a HMG CoA reductase inhibitor (HMG-CoA RI) that is eliminated by CYP3A mediated metabolism. Diltiazem is a calcium channel blocker that inhibits CYP3A and is often used concurrently with HMG-CoA RIs. The effect of IV or oral steady state diltiazem on CYP3A, as measured by lovastatin pharmacokinetics, was therefore studied in 10 healthy volunteers. Diltiazem was administered as an IV infusion over 12 h or 120 mg orally b.i.d. for two weeks. Lovastatin (20 mg) was administered before and 1 hour after the infusion or an hour after the final oral dose of diltiazem. Steady-state diltiazem serum concentrations ranged between 0.2-1.2 μM from 1-12 hours after the start of the infusion. IV diltiazem had no significant effect on lovastatin AUC0-24hr, Cmax, and tmax compared to the control treatment. Steadystate serum concentrations of diltiazem after oral administration ranged from 0.2-0.7 μM. Oral diltiazem significantly increased the lovastatin AUC0-24hr and Cmax approximately 4-fold without affecting the t1/2. The lack of effect of IV infusion suggests that diltiazem does not inhibit CYP3A systemically. The influence of diltiazem on lovastatin pharmacokinetics is consistent with an interaction that is restricted to presystemic inhibition of CYP3A in the intestinal wall.

Original languageEnglish
Pages (from-to)149
Number of pages1
JournalClinical Pharmacology and Therapeutics
Volume65
Issue number2
StatePublished - 1999

Fingerprint

Lovastatin
Diltiazem
Cytochrome P-450 CYP3A
Intravenous Infusions
Pharmacokinetics
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Calcium Channel Blockers
Serum
Oral Administration
Healthy Volunteers

ASJC Scopus subject areas

  • Pharmacology

Cite this

Jones, D. R., Azie, N. B., Masica, A., Brater, D. C., & Hall, S. D. (1999). Oral but not intravenous (IV) diltiazem impairs lovastatin clearance. Clinical Pharmacology and Therapeutics, 65(2), 149.

Oral but not intravenous (IV) diltiazem impairs lovastatin clearance. / Jones, D. R.; Azie, N. B.; Masica, A.; Brater, D. C.; Hall, S. D.

In: Clinical Pharmacology and Therapeutics, Vol. 65, No. 2, 1999, p. 149.

Research output: Contribution to journalArticle

Jones, DR, Azie, NB, Masica, A, Brater, DC & Hall, SD 1999, 'Oral but not intravenous (IV) diltiazem impairs lovastatin clearance', Clinical Pharmacology and Therapeutics, vol. 65, no. 2, pp. 149.
Jones, D. R. ; Azie, N. B. ; Masica, A. ; Brater, D. C. ; Hall, S. D. / Oral but not intravenous (IV) diltiazem impairs lovastatin clearance. In: Clinical Pharmacology and Therapeutics. 1999 ; Vol. 65, No. 2. pp. 149.
@article{cbc55a8150344d8c8f60e137a0634e6c,
title = "Oral but not intravenous (IV) diltiazem impairs lovastatin clearance",
abstract = "Lovastatin is a HMG CoA reductase inhibitor (HMG-CoA RI) that is eliminated by CYP3A mediated metabolism. Diltiazem is a calcium channel blocker that inhibits CYP3A and is often used concurrently with HMG-CoA RIs. The effect of IV or oral steady state diltiazem on CYP3A, as measured by lovastatin pharmacokinetics, was therefore studied in 10 healthy volunteers. Diltiazem was administered as an IV infusion over 12 h or 120 mg orally b.i.d. for two weeks. Lovastatin (20 mg) was administered before and 1 hour after the infusion or an hour after the final oral dose of diltiazem. Steady-state diltiazem serum concentrations ranged between 0.2-1.2 μM from 1-12 hours after the start of the infusion. IV diltiazem had no significant effect on lovastatin AUC0-24hr, Cmax, and tmax compared to the control treatment. Steadystate serum concentrations of diltiazem after oral administration ranged from 0.2-0.7 μM. Oral diltiazem significantly increased the lovastatin AUC0-24hr and Cmax approximately 4-fold without affecting the t1/2. The lack of effect of IV infusion suggests that diltiazem does not inhibit CYP3A systemically. The influence of diltiazem on lovastatin pharmacokinetics is consistent with an interaction that is restricted to presystemic inhibition of CYP3A in the intestinal wall.",
author = "Jones, {D. R.} and Azie, {N. B.} and A. Masica and Brater, {D. C.} and Hall, {S. D.}",
year = "1999",
language = "English",
volume = "65",
pages = "149",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Oral but not intravenous (IV) diltiazem impairs lovastatin clearance

AU - Jones, D. R.

AU - Azie, N. B.

AU - Masica, A.

AU - Brater, D. C.

AU - Hall, S. D.

PY - 1999

Y1 - 1999

N2 - Lovastatin is a HMG CoA reductase inhibitor (HMG-CoA RI) that is eliminated by CYP3A mediated metabolism. Diltiazem is a calcium channel blocker that inhibits CYP3A and is often used concurrently with HMG-CoA RIs. The effect of IV or oral steady state diltiazem on CYP3A, as measured by lovastatin pharmacokinetics, was therefore studied in 10 healthy volunteers. Diltiazem was administered as an IV infusion over 12 h or 120 mg orally b.i.d. for two weeks. Lovastatin (20 mg) was administered before and 1 hour after the infusion or an hour after the final oral dose of diltiazem. Steady-state diltiazem serum concentrations ranged between 0.2-1.2 μM from 1-12 hours after the start of the infusion. IV diltiazem had no significant effect on lovastatin AUC0-24hr, Cmax, and tmax compared to the control treatment. Steadystate serum concentrations of diltiazem after oral administration ranged from 0.2-0.7 μM. Oral diltiazem significantly increased the lovastatin AUC0-24hr and Cmax approximately 4-fold without affecting the t1/2. The lack of effect of IV infusion suggests that diltiazem does not inhibit CYP3A systemically. The influence of diltiazem on lovastatin pharmacokinetics is consistent with an interaction that is restricted to presystemic inhibition of CYP3A in the intestinal wall.

AB - Lovastatin is a HMG CoA reductase inhibitor (HMG-CoA RI) that is eliminated by CYP3A mediated metabolism. Diltiazem is a calcium channel blocker that inhibits CYP3A and is often used concurrently with HMG-CoA RIs. The effect of IV or oral steady state diltiazem on CYP3A, as measured by lovastatin pharmacokinetics, was therefore studied in 10 healthy volunteers. Diltiazem was administered as an IV infusion over 12 h or 120 mg orally b.i.d. for two weeks. Lovastatin (20 mg) was administered before and 1 hour after the infusion or an hour after the final oral dose of diltiazem. Steady-state diltiazem serum concentrations ranged between 0.2-1.2 μM from 1-12 hours after the start of the infusion. IV diltiazem had no significant effect on lovastatin AUC0-24hr, Cmax, and tmax compared to the control treatment. Steadystate serum concentrations of diltiazem after oral administration ranged from 0.2-0.7 μM. Oral diltiazem significantly increased the lovastatin AUC0-24hr and Cmax approximately 4-fold without affecting the t1/2. The lack of effect of IV infusion suggests that diltiazem does not inhibit CYP3A systemically. The influence of diltiazem on lovastatin pharmacokinetics is consistent with an interaction that is restricted to presystemic inhibition of CYP3A in the intestinal wall.

UR - http://www.scopus.com/inward/record.url?scp=0006378031&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0006378031&partnerID=8YFLogxK

M3 - Article

VL - 65

SP - 149

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 2

ER -